Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin plus TMP-SMX versus TMP-SMX alone for Pneumocystis pneumonia in adults with HIV
IRCT20180610040037N6Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumocystis pneumonia (PCP) and human immunodeficiency virus infection (HIV) comparing TMP-SMX + caspofungin with TMP-SMX + placebo (2 arms). Primary endpoint: All-cause mortality at day 30. Started Jul 2025; status: recruiting.
02
Drugs
caspofungintrimethoprim + sulfamethoxazole
03
Conditions
pneumocystis pneumonia (PCP)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on IRCT20180610040037N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180610040037N6.